AstraZeneca's Calquence Steps Into Blood Cancer Ring With Mighty Imbruvica

 
• By Emily Hayes

AstraZeneca's launch of BTK inhibitor Calquence (acalabrutinib) in mantle cell lymphoma will mark the company's market entry in liquid tumors, up against a formidable competitor – J&J/Abbvie's first-in-class Imbruvica.

FDA Approved typed words on a vintage typewriter

More from New Products

More from Scrip